AdipoGen Life Sciences

Liraglutide

As low as CHF 60.00

In stock

Only %1 left

AG-CP3-0034-M0011 mgCHF 60.00

AG-CP3-0034-M0055 mgCHF 165.00

AG-CP3-0034-M02525 mgCHF 450.00

AG-CP3-0034-M100100 mgCHF 1’100.00

BULK available!
Research Use Only (RUO). NOT ALLOWED FOR USE IN HUMANS.

Learn more about GLP-1 & GIP Receptor Agonists

Specifications / Handling

More Information
Product Details
Synonyms	Arg³⁴Lys²⁶-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37); NN2211; NNC 90-1170; Victoza
Product Type	Chemical
Properties
Formula	C₁₇₂H₂₆₅N₄₃O₅₁
MW	3751.2
Sequence	H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(γ-Glu-palmitoyl)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH
CAS	204656-20-2
Source/Host Chemicals	Synthetic.
Purity Chemicals	≥98% (HPLC)
Appearance	White to off-white powder.
Solubility	Freely soluble in aqueous base (>pH7). Soluble in methanol (20mg/ml) and slightly soluble in DMSO or ethanol (1mg/ml).
InChi Key	YSDQQAXHVYUZIW-QCIJIYAXSA-N
Smiles	O=C([C@H](CC(C)C)N([H])C([C@H](CC1=CN([H])C2=CC=CC=C12)N([H])C([C@H](C)N([H])C([C@H]([C@@H](C)CC)N([H])C([C@H](CC3=CC=CC=C3)N([H])C([C@H](CCC(O)=O)N([H])C([C@H](CCCCN([H])C(CC[C@@H](C(O)=O)N([H])C(CCCCCCCCCCCCCCC)=O)=O)N([H])C([C@H](C)N([H])C([C@H](C)N([H])C([C@H](CCC(N([H])[H])=O)N([H])C(CN([H])C([C@H](CCC(O)=O)N([H])C([C@H](CC(C)C)N([H])C([C@H](CC(C=C4)=CC=C4O)N([H])C([C@H](CO)N([H])C([C@H](CO)N([H])C([C@H](C(C)C)N([H])C([C@H](CC(O)=O)N([H])C([C@H](CO)N([H])C([C@H]([C@@H](C)O)N([H])C([C@H](CC5=CC=CC=C5)N([H])C([C@H]([C@@H](C)O)N([H])C(CN([H])C([C@H](CCC(O)=O)N([H])C([C@H](C)N([H])C([C@H](CC6=CN=CN6[H])N([H])[H])=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)N([H])[C@H](C(N([H])[C@H](C(N([H])CC(N([H])[C@H](C(N([H])CC(O)=O)=O)CCCN([H])/C(N([H])[H])=N/[H])=O)=O)CCCN([H])/C(N([H])[H])=N/[H])=O)C(C)C
Shipping and Handling
Shipping	AMBIENT
Short Term Storage	+4°C
Long Term Storage	-20°C
Handling Advice	Keep cool and dry.
Use/Stability	Stable for at least 1 year after receipt when stored at -20°C.
Documents
MSDS	Download PDF
Product Specification Sheet
Datasheet	Download PDF

Product-specific References

Description

Long-acting acylated glucagon-like peptide-1 (GLP-1) receptor agonist.
Antidiabetic and antiobesity agent used clinically to treat type 2 diabetes mellitus. Binding to GLP-1R, activates AMP-activated protein kinase, consequently stimulates insulin secretion in pancreatic β cells and suppresses glucagon secretion in a glucose-dependent manner. Improves control of blood glucose and consequently modulates appetite and body weight.
Inhibits β cell apoptosis and improves β cell mass.
Shown to ameliorate glycometabolism and insulin resistance through the upregulation of GLUT4.
Neuroprotective. Prevents neurodegenerative processes in pathologies such as Alzheimer's and Parkinson's disease.
Anti-inflammatory agent. Exerts cardioprotective roles via activating prosurvival pathways and suppressing inflammation. Anti-pyroptotic by inhibiting TNF-α and hypoxia-induced inflammasome activation.
Anticancer agent. Inhibited proliferation and induced apoptosis in cancer cell lines.
Shown to inhibit osteoclastogenesis.

Product References

The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men: H. Agerso, et al.; Diabetologia 45, 195 (2002)
The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice: B. Rolin, et al.; Am. J. Physiol. Endocrinol. Metab. 283, E745 (2002)
The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits beta-cell apoptosis in vitro: S. Bregenholt, et al.; BBRC 330, 577 (2005)
Pharmacokinetics and pharmacodynamics of liraglutide, a long-acting, potent glucagon-like peptide-1 analog: J. Meece; Pharmacotherapy 29, 33S (2009) (Review)
The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease: P.L. McClean, et al.; J. Neurosci. 31, 6587 (2011)
Potential role of glucagon-like peptide-1 (GLP-1) in neuroprotection: C. Hoelscher; CNS Drugs 26, 871 (2012) (Review)
Liraglutide ameliorates glycometabolism and insulin resistance through the upregulation of GLUT4 in diabetic KKAy mice: L.N. Chen, et al.; Int. J. Mol. Med. 32, 892 (2013)
Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease: P.L. McClean & C. Hoelscher; Neuropharmacol. 76, 57 (2014)
Glucagon-like peptide-1 (GLP-1) analog liraglutide inhibits endothelial cell inflammation through a calcium and AMPK dependent mechanism: N.M. Krasner, et al.; PLoS One 9, e97554 (2014)
Liraglutide acutely suppresses glucagon, lipolysis and ketogenesis in type 1 diabetes: M. Garg, et al.; Diabetes Obes. Metab. 19, 1306 (2017)
Liraglutide, a glucagon-like peptide-1 analog, induce autophagy and senescence in HepG2 cells: G.C. Krause, et al.; Eur. J. Pharmacol. 809, 32 (2017)
Liraglutide inhibits the proliferation and promotes the apoptosis of MCF-7 human breast cancer cells through downregulation of microRNA-27a expression: W. Zhao, et al.; Mol. Med. Rep. 17, 5202 (2018)
Liraglutide attenuates NLRP3 inflammasome-dependent pyroptosis via regulating SIRT1/NOX4/ROS pathway in H9c2 cells: A. Chen, et al.; BBRC 499, 267 (2018)
Liraglutide Modulates Appetite and Body Weight Via GLP-1R-Expressing Glutamatergic Neurons: J.M. Adams, et al.; Diabetes 67, 1538 (2018)
Liraglutide exerts a bone-protective effect in ovariectomized rats with streptozotocin-induced diabetes by inhibiting osteoclastogenesis: B. Wen, et al.; Exp. Ther. Med. 15, 5077 (2018)
Liraglutide protects β-cells in novel human islet spheroid models of type 1 diabetes: B. Yesildag, et al.; Clin. Immunol. 244, 109118 (2022)
Lymphatic uptake of the lipidated and non-lipidated GLP-1 agonists liraglutide and exenatide is similar in rats: S.B. Reddiar, et al.; Eur. J. Pharm. Biopharm. 200, 114339 (2024)

Call	+41 61 926 6040
Fax	+41 61 926 6049